Look­ing to pre­pare for the next flu pan­dem­ic, Sanofi drops $700M+ in­to new Toron­to fa­cil­i­ty for Flu­zone pro­duc­tion

With Covid-19 vari­ants po­ten­tial­ly stick­ing around in the hu­man pop­u­la­tion for years to come and clog­ging up hos­pi­tals, pub­lic health of­fi­cials are spot­light­ing the need for ef­fec­tive flu vac­ci­na­tion cam­paigns in­to the fu­ture. French drug­mak­er Sanofi, the mak­er of the world’s best­selling flu vac­cine Flu­zone, is now drop­ping a ma­jor in­vest­ment in­to its sup­ply chain.

Sanofi will shell out more than $703 mil­lion to build a new man­u­fac­tur­ing fa­cil­i­ty in Toron­to, the com­pa­ny an­nounced Wednes­day. The fa­cil­i­ty will be used to in­crease the sup­ply of Flu­zone, a high-dose flu vac­cine, and has the po­ten­tial to en­hance pan­dem­ic pre­pared­ness should an­oth­er oc­cur, the drug­mak­er said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER